Neuropathy News and Research

RSS

Diopsys launches new Vision Testing System to detect optic nerve disease

Diopsys, Inc. has launched the new Diopsys NOVA-DN VEP Vision Testing System to help optometrists and ophthalmologists detect optic nerve disease, including glaucoma and other neuro-visual disorders.

29 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Early intervention and close follow-up can help prevent hearing loss in children

Early intervention and close follow-up are key to rehabilitating hearing loss in children, says Paul R. Kileny, Ph.D., director of the University of Michigan's Audiology and Electrophysiology program.

25 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Sports medicine physician Steve Watts says cardiac screening for young athletes is useful in preventing sudden cardiac death and suggests new diagnostics have the potential to add value and change the debate about the viability of cardiac screening for young athletes in the United States.

17 Mar 2011

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

DJO Global, Inc., a leading provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that one of its indirect subsidiaries has signed a definitive agreement to purchase Rikco International, LLC, D/B/A Dr. Comfort, for approximately $254.6 million in cash.

15 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients.

11 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

7 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

Feet first? Old mitochondria might be responsible for neuropathy in the extremities

The burning, tingling pain of neuropathy may affect feet and hands before other body parts because the powerhouses of nerve cells that supply the extremities age and become dysfunctional as they complete the long journey to these areas, Johns Hopkins scientists suggest in a new study. The finding may eventually lead to new ways to fight neuropathy, a condition that often accompanies other diseases including HIV/AIDS, diabetes and circulatory disorders.

3 Mar 2011

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announced today that results from the global Phase III clinical study "EMBRACE" will be published online in The Lancet.

3 Mar 2011

CDA launches new awareness campaign about risk of developing type 2 diabetes

Today, the Canadian Diabetes Association launched "Get Checked Now" - a national public awareness campaign aimed at Canadians 40 and older alerting them to the consequences of being passive about their potential risk for developing type 2 diabetes and leading them to take action against the disease by getting checked now.

2 Mar 2011

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Patients in Sweden living with peripheral neuropathic pain are set to gain access to a new treatment option which can provide pain relief for up to three months following a single 30- or 60-minute application. The new treatment patch uses capsaicin - the substance found in chilli peppers which gives them their 'heat' - to change the function of pain sensing nerves in the area of skin affected.

1 Mar 2011

Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI

Sangamo BioSciences, Inc. announced today the presentation of positive preliminary clinical data from its Phase 1 trial.

1 Mar 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2010, and provided an update on its key business initiatives.

24 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011